NCT06847204View on ClinicalTrials.gov

EFFICACY OF COLCHICINE IN IMPROVING CLINICAL OUTCOMES IN PATIENTS WITH MILD TO MODERATE COVID-19 PNEUMONIA IN LAHORE: A RANDOMIZED CONTROL TRIAL

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

February 24, 2025

Primary Completion Date

May 30, 2025

Study Completion Date

June 24, 2025

Conditions
COVID - 19
Interventions
DRUG

Colchicine 0.5 MG Oral Tablet

Colchicine is anti inflammatory drug which will be given to Covid pneumonia patients and their benefit will be observed in them

Trial Locations (1)

Unknown

General hospital, Lahore

All Listed Sponsors
lead

Zaeema Kanwal

OTHER_GOV

NCT06847204 - EFFICACY OF COLCHICINE IN IMPROVING CLINICAL OUTCOMES IN PATIENTS WITH MILD TO MODERATE COVID-19 PNEUMONIA IN LAHORE: A RANDOMIZED CONTROL TRIAL | Biotech Hunter | Biotech Hunter